New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
07:31 EDTSGMO, INSY, DSCO, XLRN, GERN, ARGS, THLD, MDCO, EGRX, ANACPiper Jaffray to hold a symposium
Catalyst Symposium to be held in Boston on July 8.
News For ANAC;ARGS;DSCO;EGRX;GERN;INSY;MDCO;XLRN;SGMO;THLD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
07:57 EDTDSCODiscovery Labs receives second $1M under SBIR grant
Discovery Laboratories has received the second $1.0M tranche under a previously awarded Phase II Small Business Innovation Research, or SBIR, grant valued at up to $3.0M to support continued development of the company's aerosolized KL4 surfactant as a potential medical countermeasure to mitigate acute and chronic/late-phase radiation-induced lung injury. Discovery Labs was awarded an initial $1.0M under this grant in October 2014 and over the next year may be awarded up to an additional $1.0M following completion of certain research activities.
07:26 EDTTHLDThreshold Pharmaceuticals reports Q2 EPS (12c), consensus (14c)
Reports Q2 revenue $3.7M, consensus $3.6M.
July 29, 2015
07:10 EDTMDCOThe Medicines Co. says exploring range of strategic-partnering options
07:10 EDTMDCOThe Medicines Co. reports Q2 adjusted EPS (65c), consensus (48c)
Subscribe for More Information
06:46 EDTEGRXEagle Pharmaceuticals price target raised to $119 from $94 at Piper Jaffray
Piper Jaffray analyst David Amsellem raised his price target for Eagle Pharmaceuticals (EGRX) to $119 after analyzing the company's bendamustine products, which are enhanced forms of Teva's (TEVA) Treanda. Amsellem believes there could be "considerable upside" to his current earnings estimates for Eagle. The company's agreement with Teva provides "almost ironclad downside protection, and leaves ample room for upside," he tells investors in a research note. Further, he sees limited potential for generic entrants on Teva's forms of Treanda for the foreseeable future. Amsellem reiterates an Overweight rating on Eagle Pharmaceuticals.
July 24, 2015
16:47 EDTINSYInsys Therapeutics treatment of infantile spasms receives FDA orphan designation
Subscribe for More Information
July 23, 2015
07:15 EDTEGRXEagle Pharmaceuticals says RTU Bivalirudin NDA accepted for filing by FDA
Subscribe for More Information
July 21, 2015
10:31 EDTINSYOptions with increasing implied volatility
Options with increasing implied volatility: DUST JNUG LINE CHK CNX INSY ABX GG GDX NEM
10:01 EDTANACOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ASML (ASML) upgraded to Accumulate from Neutral at SNS Securities... Anacor (ANAC) upgraded to Buy from Neutral at Goldman... Artisan Partners (APAM) upgraded to Outperform from Neutral at Credit Suisse... Canadian National (CNI) upgraded to Buy from Hold at Canaccord... General Mills (GIS) upgraded to Outperform from Sector Perform at RBC Capital... Halliburton (HAL) upgraded to Accumulate from Neutral at Global Hunter... Harte-Hanks (HHS) upgraded to Outperform from Market Perform at BMO Capital... MDC Partners (MDCA) upgraded to Overweight from Neutral at Piper Jaffray... SABMiller (SBMRY) upgraded to Buy from Neutral at Nomura... Sanmina (SANM) upgraded to Neutral from Underperform at Longbow... Santander Mexico (BSMX) upgraded to Neutral from Sell at Goldman... Sherwin-Williams (SHW) upgraded to Buy from Neutral at Northcoast... Southwestern Energy (SWN) upgraded to Buy from Neutral at Global Hunter... Verisk Analytics (VRSK) assumed with an Outperform at Keefe Bruyette.
09:21 EDTANACOn The Fly: Pre-market Movers
Subscribe for More Information
08:36 EDTARGSArgos Therapeutics announces formation of Scientific Advisory Board
Argos Therapeutics announced the formation of the company's first Scientific Advisory Board. Jeff Abbey, president and CEO of Argos, stated, "Forming a scientific advisory board is another important step as we continue to build Argos into a fully-integrated, commercial immuno-oncology company. These oncology and immunology experts will provide us with guidance on many clinical and technical aspects of our development programs. Their input is especially welcome as we continue our pivotal phase 3 ADAPT clinical trial of our lead product candidate, AGS-003, for the treatment of metastatic renal cell carcinoma, and as we plan to begin testing AGS-003 in other tumor types."
06:40 EDTANACAnacor upgraded to Buy from Neutral at Goldman
Subscribe for More Information
July 17, 2015
10:20 EDTANACOptions with decreasing implied volatility
Options with decreasing implied volatility: ANAC RCPT UVXY GREK VIX VXX SVXY ASHR YINN SN
08:45 EDTDSCODiscovery Labs 40M share Spot Secondary priced at 60c
Stifel and H.C. Wainwright acted as joint book running managers for the offering.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use